Antibody DetailsProduct DetailsReactivity Species Human Host Species Mouse Immunogen Purified Recombinant Human IL-17 (Accession # Q16552) Formulation This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present. Storage and Handling The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months. Country of Origin USA Shipping Next Day Ambient RRIDAB_2830777 Applications and Recommended Usage? Quality Tested by Leinco Other Applications Reported In Literature ? Neutralization: This antibody is useful for neutralization of Human IL-17 bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human IL-17 (at 25 ng/ml) is 1-3 µg/ml. Immunohistochemistry: Suitable for use at concentration of 5-25 µg/mL. Immunoprecipitation: Suitable for use at concentration of 3 µg/100 µg cell lysate. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Mouse Anti-Human Interleukin 17 (IL-17) (Clone 41809) recognizes an epitope on Human IL-17. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. Background Interleukin 17 (IL-17) is a T cell cytokine that induces monocyte migration and inflammation.1 IL-17-producing cell could serve as a potential prognostic marker and a novel therapeutic target for hepatocellular carcinoma (HCC).2 IL-17 may be important in recruiting monocytes into the joints of patients with RA, supporting IL-17 as a therapeutic target in RA.1 Antigen DetailsProtein PubMed References & Citations1. Pope, RM. et al. (2009) J Immunol. 182: 3884 2. Zheng, L. et al. (2009) J Hepatol. 50(5):980-989. Technical Protocols |
Related Products
Prod No. | Description |
---|---|
I-699 |
|
I-655 |
|
I-533 |
|
I-667 |
|
I-770 |
|
I-272 |
|
I-775 |
Formats Available
